ENANTA PHARMACEUTICALS INC (ENTA)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Sep 30
In fiscal 2025, ENANTA PHARMACEUTICALS INC reported revenue of $65.32M, down 3.4% from the prior year. The company ran a net loss, with a net margin of -125.4%. It held $280.73M in total assets against $216.01M in total liabilities.
Key ratios (FY2025)
-130.7%
Operating margin
-125.4%
Net margin
-126.5%
Return on equity
-3.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.32M | $67.64M | $79.20M | $86.16M | $97.07M | $122.47M | $205.20M | $206.62M | $102.81M | $88.27M |
| Operating Income | -$85.35M | -$121.69M | -$137.21M | -$123.84M | -$109.57M | -$41.64M | $36.74M | $88.33M | $24.61M | $30.84M |
| Net Income | -$81.89M | -$116.05M | -$133.82M | -$121.75M | -$79.00M | -$36.17M | $46.38M | $71.96M | $17.71M | $21.67M |
| EPS (Diluted) | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 | $-1.81 | $2.21 | $3.48 | $0.91 | $1.13 |
| Total Assets | $280.73M | $376.65M | $462.27M | $375.41M | $438.79M | $486.13M | $489.83M | $414.23M | $326.64M | $281.28M |
| Total Liabilities | $216.01M | $247.84M | $245.54M | $54.08M | $39.36M | $30.55M | $27.34M | $20.55M | $24.96M | $11.34M |
| Shareholders' Equity | $64.72M | $128.81M | $216.74M | $321.33M | $399.43M | $455.58M | $462.49M | $393.68M | $301.68M | $269.94M |
| Cash & Equivalents | $32.30M | $37.23M | $85.39M | $43.99M | $57.21M | $87.13M | $51.23M | $63.90M | $65.67M | $16.58M |
| Operating Cash Flow | -$19.27M | -$78.76M | -$103.15M | -$84.78M | -$70.00M | $7.09M | $71.42M | $29.22M | $52.65M | $35.81M |
| Capital Expenditures | $12.90M | $17.95M | $9.06M | $2.12M | $750.0K | $1.45M | $5.42M | $2.98M | $2.51M | $4.74M |
| Shares Outstanding | 21.3K | 21.2K | 21.0K | 20.6K | 20.2K | 19.9K | 20.97M | 20.65M | 19.41M | 19.22M |